In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors

Dov Front, Einat Even‐Sapir, Ora Israel, Galina Iosilevsky, Alex Frenkel, David Milstein, Ron Epelbaum, Eliezer Robinson, Gerald M. Kolodny

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Concentrations of bleomycin labeled with cobalt 57 (Co‐bleo) over time were measured in vivo in 17 patients with 32 sites of lymphoma and 18 patients with lung tumors after administration of the same dose of bleomycin. There were marked variations in individual tumor drug concentrations even among tumors with the same histologic type, indicating that the tumor concentration of this drug in individuals cannot be predicted from the administered dose. Also, tumor concentration could not be predicted from the area under the concentration over time curve (AUC) of Co‐bleo in the blood; there was no correlation (r = 0.53) between the AUC and the concentration in the tumor at any point in time between 30 minutes and 8 hours after injection. There was no significant difference in the percent of the injected dose per milliliter (%ID/ml) which was delivered to the tumor when low and high amounts of bleomycin were administered to the same patient. Also, a good correlation (r = 0.88) between the %ID/ml over time was found when injection of low and high doses of bleomycin were compared. The results indicate that using quantitative single photon emission computed tomography (SPECT) and a labeled tracer dose it is possible to predict what fraction of the dose of a chemotherapeutic drug will concentrate in an individual patient';s tumor in vivo. They also show that, for bleomycin, escalation of dose will result in a proportional increase of tumor concentration. This increase depends on individual properties of tumors which can be measured quantitatively in vivo by SPECT and are expressed as percent of %ID/ml of tumor tissue.

Original languageEnglish (US)
Pages (from-to)2477-2483
Number of pages7
JournalCancer
Volume67
Issue number10
DOIs
StatePublished - May 15 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors'. Together they form a unique fingerprint.

  • Cite this

    Front, D., Even‐Sapir, E., Israel, O., Iosilevsky, G., Frenkel, A., Milstein, D., Epelbaum, R., Robinson, E., & Kolodny, G. M. (1991). In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. Cancer, 67(10), 2477-2483. https://doi.org/10.1002/1097-0142(19910515)67:10<2477::AID-CNCR2820671015>3.0.CO;2-D